New PrEP trial shows no HIV infections
UGANDA: In a groundbreaking development for HIV prevention, Gilead Sciences reported 100 per cent efficacy of its innovative anti-HIV drug, lenacapavir, in the PURPOSE 1 study. Conducted among 2,134 young women and adolescent girls in South Africa and Uganda, the trial revealed zero HIV infections among participants who received twice-yearly
